Lupin Q2 FY2027: EBITDA falls 10.7% YoY to INR 21,712 Mn, EBITDA margin narrows 770 bps to 27.9%
EBITDA fell 10.7% YoY to INR 21,712 Mn and EBITDA margin narrowed 770 bps to 27.9%.
By ScoutQuest · · 1 min read
- EBITDA
- INR 21,712 Mn, fell 10.7% YoY
- EBITDA Margin
- 27.9%, narrowed 770 bps
- Net Debt
- INR -33,490 Mn as on September 30, 2026
- Release
- Results press release
- Period
- Q2 FY27
_Consolidated · Q2 FY27_
💰 Net debt stood at INR -33,490 Mn as on September 30, 2026, and capital expenditure for the quarter was INR 2,230 Mn.
📌 Lupin cites IQVIA Quarter September 2026 placing it as the third largest pharmaceutical player in both the U.S. generic market and the U.S. total market by prescriptions.
⚠️ EBITDA fell 10.7% YoY to INR 21,712 Mn and EBITDA margin narrowed 770 bps to 27.9%.
Also from Lupin
Lupin Q2 FY27 investor presentation: sales up 14.0% YoY, EBITDA margin down to 25.1%
4 Nov 2026
Q2/H1 FY27 results approved; consolidated net profit ₹11,553.0 million, standalone loss ₹59.1 million
4 Nov 2026
Lupin Ltd press release
3 Nov 2026
More numbers
- Sales, Q2 FY202777,855 (INR Mn)
- EBITDA, Q2 FY202721,712 (INR Mn)
- EBITDA margin, Q2 FY202727.9%
- PBT, Q2 FY202715,796 (INR Mn)
- PAT, Q2 FY202711,553 (INR Mn)
- Net debt, as on September 30, 2026INR -33,490 Mn
- Capital expenditure, Q2 FY2027INR 2,230 Mn
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.